BioCryst Pharmaceuticals
BCRX
BCRX
230 hedge funds and large institutions have $2.07B invested in BioCryst Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 93 increasing their positions, 61 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
6% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 36
2% less funds holding
Funds holding: 234 → 230 (-4)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Holders
230
Holding in Top 10
5
Calls
$53M
Puts
$22.5M
Top Buyers
| 1 | +$271M | |
| 2 | +$23.8M | |
| 3 | +$22.8M | |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$22.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$19.8M |
Top Sellers
| 1 | -$15.4M | |
| 2 | -$15M | |
| 3 | -$11.3M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$10.5M |
| 5 |
Fisher Asset Management
Camas,
Washington
|
-$8.41M |